There’s a lot on the line this week for Sanofi Pasteur’s troubled dengue vaccine, Dengvaxia.
On Wednesday, an expert panel that advises the World Health Organization will vote to update its recommendations outlining how and when the vaccine should be used — and, more importantly, how and when it should not be administered. A decision is expected Thursday.
About the Author Reprints
